Kodiak Sciences Gain 6%

February 10, 2020 — 10:59 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Shares of clinical-stage biopharmaceutical company Kodiak Sciences Inc. (KOD) are climbing more than 6% on Monday followed by reporting additional safety, efficacy and durability data from the ongoing Phase 1b study of its investigational therapy KSI-301.

The stock touched a new high of $82.75 today morning, currently trading at $78.48.

KSI-301 is an intravitreal anti-VEGF antibody biopolymer conjugate, proposed for patients with treatment-naïve wet age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).

The results were presented by Diana V. Do, M.D., Professor of Ophthalmology at Byers Eye Institute, Stanford University School of Medicine as an oral presentation at the Angiogenesis, Exudation, and Degeneration 2020 meeting in Miami, FL.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Kodiak Sciences Gain 6%

Tags

Latest Articles